French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

A retrospective multi-center cohort study design was used to address the study objectives, using medical records obtained from three clinical centers in France.

Inclusion Criteria:Diagnosed with CML-CPAge ≥18 years at the time of CML-CP diagnosisFor 3L patients: initiated one of the following 3L therapies in CML-CP after failing on ≥2 TKIs (i.e., bosutinib, dasatinib, imatinib, nilotinib, or ponatinib) or allo-SCTFor T315I mutation patients: evidence of T315I mutation and treatment with TKI or allo-SCTExclusion Criteria:History of other active malignancies within the 3 years prior to the time of CML-CP diagnosisDocumentation of anti-cancer therapies for any other malignancies prior to the time of 3L therapy initiation or at the time of treatment initiation after identification of T315I mutationEnrollment in a clinical trial at the time of 3L therapy initiation or at the time of treatment initiation after identification of T315I mutation